The market for Centocor Inc.'s ReoPro GPIIb/IIIa inhibitor, an anti-platelet antibody, has continued to grow, with the company reporting 64 percent growth in third quarter sales by partner Eli Lilly and Co. - to $63.3 million compared to $38.5 million in the year-earlier period. ReoPro is used in 30-35 percent of all angioplasties, which about matches the size of the high-risk angioplasty indication for which it is approved.

In addition, the drug is probably used off label, particularly with stents and some non-high risk angioplasty. In the wings is FDA approval of new indications for all-comers angioplasty and refractory unstable angina patients scheduled for angioplasty.